Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 22Terminated 5Recruiting 5Unknown 2Active not recruiting 2Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 2

Conditions

Breast Neoplasms 705Carcinoma, Non-Small-Cell Lung 473Prostatic Neoplasms 423Neoplasms 384Multiple Myeloma 266Colorectal Neoplasms 257Lung Neoplasms 245Neoplasm Metastasis 234Melanoma 219Leukemia, Myeloid, Acute 193Ovarian Neoplasms 189Pancreatic Neoplasms 177Squamous Cell Carcinoma of Head and Neck 160Carcinoma, Renal Cell 146Recurrence 144Lymphoma 144Glioblastoma 142Lymphoma, Non-Hodgkin 136Stomach Neoplasms 128Triple Negative Breast Neoplasms 127Leukemia, Lymphocytic, Chronic, B-Cell 123Brain Neoplasms 123Carcinoma, Hepatocellular 122Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Urinary Bladder Neoplasms 115Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Lymphoma, Large B-Cell, Diffuse 104Sarcoma 103Lymphoma, Follicular 100

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Neurofibromatoses × Clear all
NCT03962543 2026-05-06

ReNeu

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
114 enrolled 25 charts 1 FDA
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT03873610 2025-12-26

Resiliency Training in Adolescents With NF1 and NF2

Massachusetts General Hospital

Phase NA Active not recruiting
200 enrolled
CNS

Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡